Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Clinically used RAF inhibitors are ineffective against RAS-mutant tumors.
• RAF inhibitors can paradoxically activate ERK signaling by enhancing RAF kinase dimerization.
• Overcoming drug resistance in RAF-inhibitor therapy is a significant challenge in cancer drug design.

Purpose of the Study:

• To develop a next-generation mechanistic dynamic model for analyzing RAF inhibitor combinations.
• To predict effective RAF inhibitor combinations that suppress MEK/ERK signaling in oncogenic RAS and BRAFV600E backgrounds.
• To overcome RAF dimerization-mediated resistance to RAF inhibitors.

Main Methods:

• A rule-based mechanistic dynamic model integrating thermodynamics, kinetics, structural elements, and mutational status was developed.
• The model analyzes combinations of structurally different RAF inhibitors.
• Predicted synergistic effects were experimentally validated in NRAS, HRAS, and BRAFV600E mutant cells.

Main Results:

• The model efficiently suppressed MEK/ERK signaling by predicting synergistic RAF inhibitor combinations.
• Experimental validation confirmed the predicted synergistic inhibition of ERK signaling.
• Inhibition of oncogenic RAS signaling correlated with reduced cell proliferation and colony formation.

Conclusions:

• A novel mechanistic dynamic model can predict effective RAF inhibitor combinations for targeting RAS-mutant cancers.
• Combined RAF inhibition strategies can overcome paradoxical ERK activation and drug resistance.
• Targeting the RAS/ERK pathway with novel inhibitor combinations holds promise for cancer therapy.